Adstiladrin (nadofaragene firadenovec-vncg) NDC 55566-1050

NDC codes

FDA NDC Directory

Product NDC (as listed)55566-1050Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55566-1050Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55566-1050-1	55566105001	4 VIAL in 1 CARTON (55566-1050-1) / 20 mL in 1 VIAL (55566-1050-0)Marketed from Sep 5, 2023
55566-1050-2	55566105002	20 mL in 1 VIAL (55566-1050-2)Marketed from Oct 13, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Adstiladrin
Generic name (nonproprietary): nadofaragene firadenovec-vncg
Active ingredients: Nadofaragene firadenovec — 300000000000 {VP}/mL
Dosage form: Suspension
Route: Intravesical
Labeler: Ferring Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 125700
Marketing start: Sep 5, 2023
Listing expires: Dec 31, 2027
Identifiers: Product ID 55566-1050_dac17f96-6c26-41e4-bd42-92aff75d339eSPL ID dac17f96-6c26-41e4-bd42-92aff75d339eSPL set ID 5ca20ed4-da4f-463c-ac2a-ccd6ab3774faRxCUI 2644440, 2644445UNII 0OOS09O1FH

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N455566105001 followed by a unit qualifier and the quantity

Package 55566-1050-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 24, 2026.

Indications (excerpt from the label)

ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)